The thing I really love about PCK is its revenue model. The ARR, even allowing for the miniscule drop outs, keeps growing quarter on quarter, year on year. And so far, the growth is mainly just from the aged care sector. In a year's time, the growth would come from aged care, home care, hospital, and so forth.
And then of course, there is the number of countries entering our book that is growing as well. That is why it is most important for PCK to go slowly at the start and make Australia its solid foundation for growth. All teething problems got sorted locally. In a sense, in the long term, that Covid spanner could well be a blessing in disguise for it allows the company to deal with a very manageable customer to improve its original version to the PainChek Universal.
The base is definitely set. It is now all about growing the business into other sectors and other countries. Good times ahead.
PCK Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
